ELV vs HUM

For growth investors, Elevance Health Inc.

(ELV) is the stronger pick with 12. 6% revenue growth year-over-year, versus 10. 1% for Humana Inc. (HUM). Elevance Health Inc. (ELV) offers the better valuation at 14. 7x trailing P/E (13. 8x forward), making it the more compelling value choice. Analysts rate Elevance Health Inc. (ELV) a "Buy" — based on 37 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

On trailing P/E, Elevance Health Inc.

(ELV) is the cheapest at 14. 7x versus Humana Inc. at 24. 3x. On forward P/E, Elevance Health Inc. is actually cheaper at 13. 8x.

Over the past 5 years, Elevance Health Inc.

(ELV) delivered a total return of +2. 4%, compared to -44. 3% for Humana Inc. (HUM). Over 10 years, the gap is even starker: ELV returned +202. 3% versus HUM's +52. 9%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), Elevance Health Inc.

(ELV) is the lower-risk stock at 0. 46β versus Humana Inc. 's 0. 56β — meaning HUM is approximately 22% more volatile than ELV relative to the S&P 500. On balance sheet safety, Humana Inc. (HUM) carries a lower debt/equity ratio of 73% versus 75% for Elevance Health Inc. — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), Elevance Health Inc.

(ELV) is pulling ahead at 12. 6% versus 10. 1% for Humana Inc. (HUM). On earnings-per-share growth, the picture is similar: Humana Inc. grew EPS -1. 4% year-over-year, compared to -2. 2% for Elevance Health Inc.. Over a 3-year CAGR, HUM leads at 11. 7% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

Elevance Health Inc.

(ELV) is the more profitable company, earning 2. 8% net margin versus 0. 9% for Humana Inc. — meaning it keeps 2. 8% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: ELV leads at 4. 1% versus 1. 1% for HUM. At the gross margin level — before operating expenses — ELV leads at 25. 6%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

On forward earnings alone, Elevance Health Inc.

(ELV) trades at 13. 8x forward P/E versus 26. 8x for Humana Inc. — 13. 0x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for ELV: 3. 6% to $382. 38.

All stocks in this comparison pay dividends.

Elevance Health Inc. (ELV) offers the highest yield at 1. 9%, versus 1. 5% for Humana Inc. (HUM).

For long-horizon retirement investors, Elevance Health Inc.

(ELV) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0. 46), 1. 9% yield, +202. 3% 10Y return). Both have compounded well over 10 years (ELV: +202. 3%, HUM: +52. 9%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.

In terms of investment character: ELV is a mid-cap deep-value stock; HUM is a mid-cap quality compounder stock. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.